Earnings and Analyst Expectations - Johnson & Johnson (JNJ) is set to report earnings with analysts expecting revenue and profit growth compared to the same period last year [2] - Revenue is expected to rise to $22.51 billion from $21.4 billion, and net income to $4.4 billion from $4.05 billion in Q4 2023 [3] - Analysts are cautiously optimistic, with 6 out of 12 analysts giving a "buy" rating and 6 giving a "hold" rating, with an average price target of $175 implying 19% upside from Friday's close [2] Stock Performance - Johnson & Johnson shares trended lower from mid-October through the end of 2024, ending the year down nearly 8% [3] - The stock has gained close to 2% in January, closing at $147.03 as of Friday [3] Challenges and Risks - The company faces unresolved class action lawsuits related to its talc powder, with hearings scheduled early this year to determine the fate of a subsidiary's bankruptcy plan and a multi-billion dollar settlement [4] - An expiring patent for one of its popular drugs is expected to bring competition [4] - The company's AAA credit rating is at risk due to recent acquisitions, including the $14.6 billion deal to acquire Intra-Cellular Therapies (ITCI), which is expected to be financed with a combination of cash and debt [5] Strategic Moves - Johnson & Johnson made several acquisitions in 2024 and started 2025 with the acquisition of Intra-Cellular Therapies (ITCI) for $14.6 billion, expected to close this year [5]

Shareholders That Lost Money on Johnson & Johnson (JNJ) Should Contact Levi & Korsinsky About Securities Fraud Investigation - JNJ ...

Johnson & Johnson (JNJ) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation ...

Shareholder Rights Advocates at Levi & Korsinsky Investigate Johnson & Johnson (JNJ) Regarding Possible Securities Fraud Violations ...

Sundry Photography Introduction Johnson & Johnson (NYSE:JNJ), which offers a range of healthcare solutions across the globe, hasn’t done a great deal of good for its shareholders over the past year. Admittedly, even other healthcare stocks from the S&P500 (XLV) have hardly dazzled either, generating positive returns of just low single digits (on average), when the benchmark has surged by +24%. However, JNJ has fared a lot worse, by consistently underperforming XLV through the year, and eventually erodin ...

Analysts on Wall Street project that Johnson & Johnson (JNJ) will announce quarterly earnings of $2 per share in its forthcoming report, representing a decline of 12.7% year over year. Revenues are projected to reach $22.54 billion, increasing 5.4% from the same quarter last year.Over the past 30 days, the consensus EPS estimate for the quarter has remained unchanged. This demonstrates the covering analysts' collective reassessment of their initial projections during this period.Before a company reveals its ...

Bronstein, Gewirtz & Grossman, LLC Is Investigating Johnson & Johnson (JNJ) And Encourages Investors to Connect ...

Johnson & Johnson (JNJ) has initiated a rolling submission with the FDA seeking approval for TAR-200, its investigational drug-device combination to treat certain patients with non-muscle invasive bladder cancer (NMIBC).The J&J filing seeks the FDA’s nod for TAR-200 as a single agent to treat patients with BCG-unresponsive, high-risk NMIBC with carcinoma in-situ (CIS), with or without papillary tumors. If approved, TAR-200 will be the first intravesical drug-releasing system in the given indication.The FDA ...

Industry Overview - The global pharmaceutical industry is valued at $1.4 trillion and is expected to grow at an annual rate of 6.1% through 2030 [1] - The industry is considered a cornerstone of healthcare, with strong staying power and long-term investment potential [1] Pfizer (PFE) - Pfizer has a rich history dating back to the mid-1800s and remains one of the leading pharmaceutical companies [3] - The company's COVID-19 vaccine (Comirnaty) and treatment (Paxlovid) generated $56.7 billion in sales at their peak in 2022 [3] - Pfizer is focusing on its oncology pipeline for future growth, following its $43 billion acquisition of Seagen in 2023 [4] - Analysts expect Pfizer to grow earnings by an average of 14% annually over the next three to five years [4] - The stock offers a dividend yield of 6.3% with a strong payout ratio of 57% of earnings [5] - Pfizer's stock is valued at less than 10 times forward earnings estimates, indicating potential for double-digit total investment returns [5] Johnson & Johnson (JNJ) - Johnson & Johnson is a diversified healthcare company with a strong pharmaceutical core and a MedTech segment [6] - The company spun off its consumer products business as Kenvue in August 2023 [6] - Johnson & Johnson is a Dividend King with 62 consecutive annual dividend increases [6] - The company's growth is driven by innovation, acquisitions, and share repurchases, resulting in slow but steady earnings growth [7] - Johnson & Johnson's stock trades at a forward P/E ratio of just over 13, with analysts expecting 5% to 6% annualized long-term earnings growth [8] - The stock offers a 3.5% dividend yield and is expected to produce 6% to 10% annualized returns, making it a reliable long-term investment [8]

The JP Morgan Healthcare Conference, which is being held in San Francisco this year, has been much more active than last year. Among some of the top news at the conference were M&A deal announcements by J&J (JNJ) , Eli Lilly (LLY) and GSK (GSK) .While J&J announced a big deal to acquire neuroscience company Intra-Cellular Therapies (ITCI) , Lilly and GSK announced smaller deals.J&J Offers to Buy ITCI for $14BThe drug and medical devices giant entered into a definitive agreement to acquire Intra-Cellular The ...